Literature DB >> 24782256

Interferon-combination strategies for the treatment of chronic hepatitis C.

Andrew Aronsohn1, Donald Jensen1.   

Abstract

Direct acting antiviral agents have revolutionized hepatitis C (HCV) therapy. Many agents that are either currently available or undergoing investigation offer higher rates of sustained virologic response, reduced toxicity and shorter duration of therapy when compared to traditional treatment consisting of pegylated interferon and ribavirin. Although interferon free therapy may be a preferred option, some patients may still require an interferon based regimen to ensure efficacy. In this review, we discuss therapeutic strategies which utilize various combinations of protease inhibitors, NS5A inhibitors, nucleotide polymerase inhibitors and non-nucleoside polymerase inhibitors along with pegylated interferon in the treatment of chronic HCV. Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24782256     DOI: 10.1055/s-0034-1371008

Source DB:  PubMed          Journal:  Semin Liver Dis        ISSN: 0272-8087            Impact factor:   6.115


  5 in total

1.  Chaperone-Mediated Autophagy Targets IFNAR1 for Lysosomal Degradation in Free Fatty Acid Treated HCV Cell Culture.

Authors:  Ramazan Kurt; Partha K Chandra; Fatma Aboulnasr; Rajesh Panigrahi; Pauline Ferraris; Yucel Aydin; Krzysztof Reiss; Tong Wu; Luis A Balart; Srikanta Dash
Journal:  PLoS One       Date:  2015-05-11       Impact factor: 3.240

2.  Silybin supplementation during HCV therapy with pegylated interferon-α plus ribavirin reduces depression and anxiety and increases work ability.

Authors:  Giulia Malaguarnera; Gaetano Bertino; Giuseppe Chisari; Massimo Motta; Michele Vecchio; Marco Vacante; Filippo Caraci; Carmela Greco; Filippo Drago; Giuseppe Nunnari; Michele Malaguarnera
Journal:  BMC Psychiatry       Date:  2016-11-15       Impact factor: 3.630

3.  Telementoring of primary care providers delivering hepatitis C treatment in New York City: Results from Project INSPIRE.

Authors:  Paul A Teixeira; Marie P Bresnahan; Fabienne Laraque; Alain H Litwin; Shuchin J Shukla; Jonathan M Schwartz; Sheila Reynoso; Ponni V Perumalswami; Jeffrey M Weiss; Brooke Wyatt; Bruce R Schackman
Journal:  Learn Health Syst       Date:  2018-05-10

4.  Somatic pain associated with initiation of interferon-alpha (IFN-α) plus ribavirin (RBV) therapy in chronic HCV patients: A prospective study.

Authors:  Chih Ying Lin; Ta-Wei Guu; Hsueh-Chou Lai; Cheng-Yuan Peng; Jill Yi-Ju Chiang; Hui-Ting Chen; Tsai-Chung Li; Shing-Yu Yang; Kuan-Pin Su; Jane Pei-Chen Chang
Journal:  Brain Behav Immun Health       Date:  2020-01-03

5.  Antiretroviral Drugs Alter the Content of Extracellular Vesicles from HIV-1-Infected Cells.

Authors:  Catherine DeMarino; Michelle L Pleet; Maria Cowen; Robert A Barclay; Yao Akpamagbo; James Erickson; Nicaise Ndembi; Manhattan Charurat; Jibreel Jumare; Sunday Bwala; Peter Alabi; Max Hogan; Archana Gupta; Nicole Noren Hooten; Michele K Evans; Benjamin Lepene; Weidong Zhou; Massimo Caputi; Fabio Romerio; Walter Royal; Nazira El-Hage; Lance A Liotta; Fatah Kashanchi
Journal:  Sci Rep       Date:  2018-05-16       Impact factor: 4.379

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.